Therapeutic evaluation of etanercept in a model of traumatic brain injury

Chung Ching Chio, Jia Wei Lin, Ming Wen Chang, Che Chuan Wang, Jinn Rung Kuo, Chung Zhing Yang, Ching Ping Chang

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Antagonism of tumor necrosis factor-alpha with etanercept has proved to be effective in the treatment of spinal cord injury and centrally endotoxin-induced brain injury. However, etanercept may offer promise as therapy for traumatic brain injury (TBI). In this study, anesthetized rats, immediately after the onset of TBI, were divided into two major groups and given the vehicle solution (1 mL/kg of body weight) or etanercept (5 mg/kg of body weight) intraperitoneally once per 12 h for consecutive 3 days. Etanercept caused attenuation of TBI-induced cerebral ischemia (e.g., increased cellular levels of glutamate and lactate-to-pyruvate ratio), damage (e.g., increased cellular levels of glycerol) and contusion and motor and cognitive function deficits. TBI-induced neuronal apoptosis (e.g., increased numbers of terminal deoxynucleotidyl transferase αUTP nick-end labeling and neuronal-specific nuclear protein double-positive cells), glial apoptosis (e.g., increased numbers of terminal deoxynucleotidyl transferase αUTP nick-end labeling and glial fibrillary acidic protein double-positive cells), astrocytic (e.g., increased numbers of glial fibrillary acidic protein positive cells) and microglial (e.g., increased numbers of ionized calcium-binding adapter molecule 1-positive cells) activation and activated inflammation (e.g., increased levels of tumor necrosis factor-alpha, interleukin-1β and interleukin-6) were all significantly reduced by etanercept treatment. These findings suggest that etanercept may improve outcomes of TBI by penetrating into the cerebrospinal fluid in rats.

Original languageEnglish
Pages (from-to)921-929
Number of pages9
JournalJournal of Neurochemistry
Volume115
Issue number4
DOIs
Publication statusPublished - Nov 2010

Fingerprint

Brain
Uridine Triphosphate
DNA Nucleotidylexotransferase
Glial Fibrillary Acidic Protein
Cells
Labeling
Rats
Therapeutics
Tumor Necrosis Factor-alpha
Body Weight
Apoptosis
Cerebrospinal fluid
Contusions
Nuclear Proteins
Brain Ischemia
Pyruvic Acid
Spinal Cord Injuries
Interleukin-1
Endotoxins
Neuroglia

Keywords

  • Apoptosis
  • Etanercept
  • Inflammation
  • Traumatic brain injury
  • Tumor necrosis factor-alpha

ASJC Scopus subject areas

  • Biochemistry
  • Cellular and Molecular Neuroscience

Cite this

Chio, C. C., Lin, J. W., Chang, M. W., Wang, C. C., Kuo, J. R., Yang, C. Z., & Chang, C. P. (2010). Therapeutic evaluation of etanercept in a model of traumatic brain injury. Journal of Neurochemistry, 115(4), 921-929. https://doi.org/10.1111/j.1471-4159.2010.06969.x

Therapeutic evaluation of etanercept in a model of traumatic brain injury. / Chio, Chung Ching; Lin, Jia Wei; Chang, Ming Wen; Wang, Che Chuan; Kuo, Jinn Rung; Yang, Chung Zhing; Chang, Ching Ping.

In: Journal of Neurochemistry, Vol. 115, No. 4, 11.2010, p. 921-929.

Research output: Contribution to journalArticle

Chio, Chung Ching ; Lin, Jia Wei ; Chang, Ming Wen ; Wang, Che Chuan ; Kuo, Jinn Rung ; Yang, Chung Zhing ; Chang, Ching Ping. / Therapeutic evaluation of etanercept in a model of traumatic brain injury. In: Journal of Neurochemistry. 2010 ; Vol. 115, No. 4. pp. 921-929.
@article{321f67a0174a4fc8a6d0dac1f21edd72,
title = "Therapeutic evaluation of etanercept in a model of traumatic brain injury",
abstract = "Antagonism of tumor necrosis factor-alpha with etanercept has proved to be effective in the treatment of spinal cord injury and centrally endotoxin-induced brain injury. However, etanercept may offer promise as therapy for traumatic brain injury (TBI). In this study, anesthetized rats, immediately after the onset of TBI, were divided into two major groups and given the vehicle solution (1 mL/kg of body weight) or etanercept (5 mg/kg of body weight) intraperitoneally once per 12 h for consecutive 3 days. Etanercept caused attenuation of TBI-induced cerebral ischemia (e.g., increased cellular levels of glutamate and lactate-to-pyruvate ratio), damage (e.g., increased cellular levels of glycerol) and contusion and motor and cognitive function deficits. TBI-induced neuronal apoptosis (e.g., increased numbers of terminal deoxynucleotidyl transferase αUTP nick-end labeling and neuronal-specific nuclear protein double-positive cells), glial apoptosis (e.g., increased numbers of terminal deoxynucleotidyl transferase αUTP nick-end labeling and glial fibrillary acidic protein double-positive cells), astrocytic (e.g., increased numbers of glial fibrillary acidic protein positive cells) and microglial (e.g., increased numbers of ionized calcium-binding adapter molecule 1-positive cells) activation and activated inflammation (e.g., increased levels of tumor necrosis factor-alpha, interleukin-1β and interleukin-6) were all significantly reduced by etanercept treatment. These findings suggest that etanercept may improve outcomes of TBI by penetrating into the cerebrospinal fluid in rats.",
keywords = "Apoptosis, Etanercept, Inflammation, Traumatic brain injury, Tumor necrosis factor-alpha",
author = "Chio, {Chung Ching} and Lin, {Jia Wei} and Chang, {Ming Wen} and Wang, {Che Chuan} and Kuo, {Jinn Rung} and Yang, {Chung Zhing} and Chang, {Ching Ping}",
year = "2010",
month = "11",
doi = "10.1111/j.1471-4159.2010.06969.x",
language = "English",
volume = "115",
pages = "921--929",
journal = "Journal of Neurochemistry",
issn = "0022-3042",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Therapeutic evaluation of etanercept in a model of traumatic brain injury

AU - Chio, Chung Ching

AU - Lin, Jia Wei

AU - Chang, Ming Wen

AU - Wang, Che Chuan

AU - Kuo, Jinn Rung

AU - Yang, Chung Zhing

AU - Chang, Ching Ping

PY - 2010/11

Y1 - 2010/11

N2 - Antagonism of tumor necrosis factor-alpha with etanercept has proved to be effective in the treatment of spinal cord injury and centrally endotoxin-induced brain injury. However, etanercept may offer promise as therapy for traumatic brain injury (TBI). In this study, anesthetized rats, immediately after the onset of TBI, were divided into two major groups and given the vehicle solution (1 mL/kg of body weight) or etanercept (5 mg/kg of body weight) intraperitoneally once per 12 h for consecutive 3 days. Etanercept caused attenuation of TBI-induced cerebral ischemia (e.g., increased cellular levels of glutamate and lactate-to-pyruvate ratio), damage (e.g., increased cellular levels of glycerol) and contusion and motor and cognitive function deficits. TBI-induced neuronal apoptosis (e.g., increased numbers of terminal deoxynucleotidyl transferase αUTP nick-end labeling and neuronal-specific nuclear protein double-positive cells), glial apoptosis (e.g., increased numbers of terminal deoxynucleotidyl transferase αUTP nick-end labeling and glial fibrillary acidic protein double-positive cells), astrocytic (e.g., increased numbers of glial fibrillary acidic protein positive cells) and microglial (e.g., increased numbers of ionized calcium-binding adapter molecule 1-positive cells) activation and activated inflammation (e.g., increased levels of tumor necrosis factor-alpha, interleukin-1β and interleukin-6) were all significantly reduced by etanercept treatment. These findings suggest that etanercept may improve outcomes of TBI by penetrating into the cerebrospinal fluid in rats.

AB - Antagonism of tumor necrosis factor-alpha with etanercept has proved to be effective in the treatment of spinal cord injury and centrally endotoxin-induced brain injury. However, etanercept may offer promise as therapy for traumatic brain injury (TBI). In this study, anesthetized rats, immediately after the onset of TBI, were divided into two major groups and given the vehicle solution (1 mL/kg of body weight) or etanercept (5 mg/kg of body weight) intraperitoneally once per 12 h for consecutive 3 days. Etanercept caused attenuation of TBI-induced cerebral ischemia (e.g., increased cellular levels of glutamate and lactate-to-pyruvate ratio), damage (e.g., increased cellular levels of glycerol) and contusion and motor and cognitive function deficits. TBI-induced neuronal apoptosis (e.g., increased numbers of terminal deoxynucleotidyl transferase αUTP nick-end labeling and neuronal-specific nuclear protein double-positive cells), glial apoptosis (e.g., increased numbers of terminal deoxynucleotidyl transferase αUTP nick-end labeling and glial fibrillary acidic protein double-positive cells), astrocytic (e.g., increased numbers of glial fibrillary acidic protein positive cells) and microglial (e.g., increased numbers of ionized calcium-binding adapter molecule 1-positive cells) activation and activated inflammation (e.g., increased levels of tumor necrosis factor-alpha, interleukin-1β and interleukin-6) were all significantly reduced by etanercept treatment. These findings suggest that etanercept may improve outcomes of TBI by penetrating into the cerebrospinal fluid in rats.

KW - Apoptosis

KW - Etanercept

KW - Inflammation

KW - Traumatic brain injury

KW - Tumor necrosis factor-alpha

UR - http://www.scopus.com/inward/record.url?scp=77958542029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958542029&partnerID=8YFLogxK

U2 - 10.1111/j.1471-4159.2010.06969.x

DO - 10.1111/j.1471-4159.2010.06969.x

M3 - Article

C2 - 20796174

AN - SCOPUS:77958542029

VL - 115

SP - 921

EP - 929

JO - Journal of Neurochemistry

JF - Journal of Neurochemistry

SN - 0022-3042

IS - 4

ER -